Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone650-550-3500
Debt
Debt-to-Equity Ratio0.15
Current Ratio2.39
Quick Ratio2.39
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.90 million
Price / Sales2.17
Cash FlowN/A
Price / Cash FlowN/A
Book Value($11.02) per share
Price / Book-0.25
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-3,400,000.00
Net Margins-330.79%
Return on Equity-198.56%
Return on Assets-40.81%
Miscellaneous
Employees16
Outstanding Shares7,140,000
Market Cap$21.42 million
OptionableNot Optionable
Vaxart (NASDAQ:VXRT) Frequently Asked Questions
What is Vaxart's stock symbol?
Vaxart trades on the NASDAQ under the ticker symbol "VXRT."
When did Vaxart's stock split? How did Vaxart's stock split work?
Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.
How were Vaxart's earnings last quarter?
Vaxart Inc (NASDAQ:VXRT) issued its quarterly earnings results on Friday, November, 9th. The biotechnology company reported ($0.92) earnings per share for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Vaxart had a negative return on equity of 198.56% and a negative net margin of 330.79%. View Vaxart's Earnings History.
When is Vaxart's next earnings date?
Has Vaxart been receiving favorable news coverage?
News articles about VXRT stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Vaxart earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the near future.
Who are some of Vaxart's key competitors?
Some companies that are related to Vaxart include Aptose Biosciences (APTO), Aevi Genomic Medicine (GNMX), BioCardia (BCDA), Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX), Genocea Biosciences (GNCA), Arsanis (ASNS), Oncobiologics (ONS), BIONDVAX PHARMA/S (BVXV), AVITA MED LTD/S (AVMXY), TRACON Pharmaceuticals (TCON), Proteon Therapeutics (PRTO), Vical (VICL), Curis (CRIS) and Titan Pharmaceuticals (TTNP).
Who are Vaxart's key executives?
Vaxart's management team includes the folowing people:
- Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO & Director (Age 60)
- Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 50)
- Mr. John M. Harland M.B.A., CPA, CFO & Sec. (Age 66)
- Mr. Brant Biehn, Sr. VP of Commercial Operations
- Dr. David N. Taylor, Chief Medical Officer (Age 69)
Who are Vaxart's major shareholders?
Which institutional investors are buying Vaxart stock?
How do I buy shares of Vaxart?
Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vaxart's stock price today?
One share of VXRT stock can currently be purchased for approximately $2.70.
How big of a company is Vaxart?
Vaxart has a market capitalization of $21.42 million and generates $8.90 million in revenue each year. Vaxart employs 16 workers across the globe.
What is Vaxart's official website?
How can I contact Vaxart?
Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]
MarketBeat Community Rating for Vaxart (NASDAQ VXRT)
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
